As finance nerds would already know, the accrual ratio from cashflow is a key measure for assessing how well a company's free cash flow (FCF) matches its profit. The accrual ratio subtracts the FCF ...

Sarepta Therapeutics SRPT posted third-quarter 2024 adjusted earnings per share (EPS) of 62 cents, which beat the Zacks ...

Sarepta Therapeutics is advancing SRP-9003 gene therapy for LGMD, with phase 3 study results expected in early 2025. Learn ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Sarepta Therapeutics (SRPT – Research Report) and DocGo (DCGO – Research Report) with bullish sentiments.

Sarepta Therapeutics Inc (SRPT) reports a robust 39% revenue growth, achieving profitability while navigating strategic ...

William Blair analyst Sami Corwin has maintained their bullish stance on SRPT stock, giving a Buy rating today. Sami Corwin’s rating is ...

Sarepta Therapeutics (SRPT) reported $467.17 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 40.8%. EPS of $0.62 for the same period compares to -$0.

Investors in Sarepta Therapeutics Inc (Symbol: SRPT) saw new options begin trading today, for the December 13th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...